1
|
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L. Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. Ther Adv Med Oncol 2022; 14:17588359221141307. [PMID: 36601631 PMCID: PMC9806434 DOI: 10.1177/17588359221141307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Accepted: 11/07/2022] [Indexed: 12/28/2022] Open
Abstract
Background Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC), but results are still inconsistent. The PRODIGE 9 phase III study compared bevacizumab maintenance versus observation alone after induction chemotherapy with FOLFIRI plus bevacizumab. Objective We evaluated the impact of SNPs of VEGF-A, VEGF receptors (VEGFR-1, VEGFR-2), and hypoxia inducible factor-1α (HIF-1α) on tumor control duration (TCD), overall survival (OS), progression-free survival (PFS), and duration of first chemotherapy free-intervals (CFI). Patients and methods We included 314/491 patients from PRODIGE 9 with a DNA blood sample available. Nine SNPs were genotyped on germline DNA using real-time Polymerase Chain Reaction TaqMan TM (Thermo Fisher Scientific, Waltham, MA , USA 02451). Results In the bevacizumab arm, patients with the VEGFR-1 rs9582036 CC genotype (n = 14) had significantly longer TCD [22.4 months (95% confidence interval (CI): 14.75-not reached)] than patients with the AA or CA genotype [14.4 months (95% CI: 11.7-17.1)] (p = 0.036), whereas there was no significant difference in the observation arm. In the bevacizumab arm, no significant difference was found between the CC, and AA or CA genotype for OS [28.2 (95% CI: 18.1-42.8) versus 22.5 (95% CI: 18.6-24.6) months, p = 0.5], PFS [9.4 (95% CI: 7.2-11.3) versus 9.2 (95% CI: 8.71-10.1)], and duration of the first CFI [4.6 (95% CI: 1.6-13.3) versus 4.14 (95% CI: 0.5-29.0) months, p = 0.3]. Conclusion Among mCRC patients treated with bevacizumab maintenance, those with the VEGFR-1 rs9582036 CC genotype experienced longer TCD. The presence of this genotype may thus predict a benefit of bevacizumab maintenance in mCRC.
Collapse
Affiliation(s)
| | - Camille Sibertin-Blanc
- UMR S-910 INSERM, Génétique Médicale et
Génomique Fonctionnelle, Aix-Marseille Université, Marseille, France,Hôpital Sainte Musse, Centre Hospitalier
Intercommunal Toulon 6 La Seyne-sur-Mer, Toulon, France
| | - Aurélie Fabre
- UMR S-910 INSERM, Génétique Médicale et
Génomique Fonctionnelle, Aix-Marseille Université, Marseille, France
| | - Karine Le Malicot
- Département de Statistique, Fédération
Française de Cancérologie Digestive (FFCD), Dijon, France
| | | | | | - Julien Taïeb
- Hôpital Européen Georges Pompidou – Université
Paris-Cité, SIRIC CARPEM, Paris, France
| | - Valérie Boige
- Department of Cancer Medicine, Gustave Roussy,
Villejuif, France
| | - Olivier Bouché
- Service de Gastroentérologie et Oncologie
Digestive, CHU Reims, Reims, France
| | | | - Roger Faroux
- Centre Hospitalier les Oudairies, La
Roche-sur-Yon, France
| | | | | | | | - Claire Mulot
- CRB EPIGENETEC, Centre de Recherche des
Cordeliers, INSERM U1138 – Université de Paris, La Sorbonne, Paris,
France
| | - Sylviane Olschwang
- Hôpital Privé Clairval, Ramsay Santé,
Marseille, France Medipath, Eguilles, France
| | - Jean-François Seitz
- Hôpital la Timone, Assistance Publique
Hôpitaux de Marseille – Aix-Marseille Université, Marseille, France,UMR S-910 INSERM, Génétique Médicale et
Génomique Fonctionnelle, Aix-Marseille Université, Marseille, France
| | | | | |
Collapse
|
2
|
Wang F, Liu G. Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer. Int J Gen Med 2022; 15:5651-5659. [PMID: 35734201 PMCID: PMC9208669 DOI: 10.2147/ijgm.s362366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Accepted: 04/21/2022] [Indexed: 11/23/2022] Open
Abstract
Objective Bevacizumab is usually considered a first-line anti-tumor therapy, which inhibits tumor growth by downregulating the vascular endothelial growth factor (VEGF) that further silences the activity of the kinase insert region receptor (KDR) gene. In the current study, we investigated the treatment response of bevacizumab in advanced colorectal cancer (CRC) patients bearing 889 C>T mutation in the KDR gene. Methods A total of 135 advanced CRC patients were treated with bevacizumab along with chemotherapy at the seventh medical center of the People’s Liberation Army general hospital from January 2012 to June 2021 and were analyzed retrospectively. The KDR genotyping and mRNA expression analyses were performed in 57 patients. Results The KDR genotyping revealed 97 (71.85%) cases with CC genotype, 34 (25.19%) cases with CT, and 4 (2.96%) cases with TT genotype, while the minor allele frequency of 889 C>T was found as 0.16. The median progression-free survival (PFS) of the patients with CT/TT genotype and CC genotype was found to be 6.1 and 9.7 months, respectively (P = 0.009). The median overall survival (OS) of the two genotypes was 13.7 and 19.7 (P = 0.025), respectively. Multivariable Cox regression analysis of PFS, CT/TT genotype was found to be an independent factor for PFS (odds ratio (OR) = 1.88, P = 0.023). Additionally, the mRNA expression of KDR in 57 biopsies taken from patients with CT/TT genotypes was significantly higher than that of patients with CC genotype (P < 0.001). Additionally, in terms of safety, 55 patients experienced grade 2 or higher fatigue (incidence rate 40.74%) after receiving bevacizumab along with chemotherapy. Conclusion The 889 C>T mutation in KDR gene affects the KDR expression in colorectal cancer patients, thereby affecting the effectiveness of bevacizumab therapy.
Collapse
Affiliation(s)
- Fei Wang
- Department of Oncology, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing, People's Republic of China
| | - Gang Liu
- Department of General Surgery, The First Medical Center of People's Liberation Army General Hospital, Beijing, People's Republic of China
| |
Collapse
|
3
|
Han F, Tian H, Jin B, Chen G. Influence of GSTP1 Polymorphism on the Clinical Outcomes of Patients With Advanced NSCLC Receiving First-Line Bevacizumab-Based Regimen: A Real-World Retrospective Study. Clin Med Insights Oncol 2021; 15:11795549211059146. [PMID: 34924779 PMCID: PMC8679038 DOI: 10.1177/11795549211059146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Accepted: 10/18/2021] [Indexed: 11/15/2022] Open
Abstract
Background: This study was to investigate the influence of GSTP1 gene polymorphism on the
clinical outcomes of patients with advanced non-small-cell lung cancer
(NSCLC) receiving first-line bevacizumab plus chemotherapy regimen. Methods: A total of 128 patients with advanced NSCLC who were administered with
bevacizumab-based first-line regimens were recruited in this study.
Available blood specimen and peripheral blood mononuclear cells (PBMCs) of
the patients were obtained for the analysis of polymorphism and GSTP1 gene
mRNA expression, respectively. The association between genotype status and
clinical outcomes and other variates was analyzed and presented. Results: The prevalence of rs1695 were in accordance with Hardy-Weinberg Equilibrium
(P = .978). Patients with GG and AG genotypes were
merged in a pattern of dominant inheritance to seek for the potentially
clinical significance. Analysis of efficacy exhibited that the objective
response rate (ORR) of patients with AA genotype and AG/GG genotypes were
62.1% (54/87) and 51.2% (21/41) (P = 0.245). Prognosis
demonstrated that the median progression-free survival (PFS) of patients
with AA genotype and AG/GG genotypes were 9.5 and 5.6 months, respectively
(P = .007). Furthermore, the median overall survival
(OS) of the two genotypes were 22.0 and 16.6 months, respectively
(P = .003). In addition, adjusted in multivariate Cox
analysis for OS, AG/GG genotype was an independent factor for OS.
Interestingly, mRNA analysis suggested that the mRNA expression of GSTP1 in
PBMC of the patients with AG/GG genotypes of rs1695 polymorphism was
significantly higher than those of patients with AA genotype
(P < .001). Conclusion: GSTP1 polymorphism rs1695 could be used for the prognostic evaluation of
patients with advanced NSCLC receiving bevacizumab combined chemotherapy
regimen.
Collapse
Affiliation(s)
- Fei Han
- Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, P.R. China
| | - Hanji Tian
- Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, P.R. China
| | - Baoli Jin
- Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, P.R. China
| | - Gang Chen
- Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, P.R. China
| |
Collapse
|